ARE ESTROGEN ASSAYS ESSENTIAL FOR MONITORING GONADOTROPIN STIMULANT THERAPY

被引：20

作者：

HARDIMAN, P

THOMAS, M

OSGOOD, V

VLASSOPOULOU, V

GINSBURG, J

机构：

[1] Department of Endocrinology, Royal Free Hospital Medical School, London

[2] Department of Chemical Pathology and Human Metabolism, Royal Free Hospital Medical School, London

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1990年 / 4卷 / 04期

关键词：

D O I：

10.3109/09513599009024980

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ovarian responses to human menopausal gonadotropin (hMG) are conventionally monitored by urinary estrogen or serum estradiol (E2) concentration. E2 can also be measured in saliva but this is rarely used. With ultrasound (USS) however, follicular development is assessed directly and we have previously shown that USS is superior to urinary estrogens for monitoring. We have now compared salivary and serum E2 with USS during hMG therapy in 48 women over 101 cycles. Salivary and serum E2 correlated significantly with each other and with the number of mature follicles. The manufacturers of hMG state that hCG should be given only when E2 is between 100 and 3000 pmol/1. However, there were no mature follicles in 40% of the cycles where E2 lay within this range. USS is the most accurate method of monitoring responses to hMG and, where this is available, estrogen assay provides no additional useful information.

引用

页码：261 / 269

页数：9

共 10 条

[1]

Shaaban M.M., Klopper A., A study on monitoring of gonadotropin therapy by the assay of plasma oestradiol and progesterone, J. Obstet. Gynaecol. Br. Commonw, 80, (1973)

[2]

Fink R.S., Bowes L.P., Mackintosh C.E., Smith W.I., Georgiades E., Ginsburg J., The value of ultrasound for monitoring ovarian responses to gonadotrophin stimulant therapy, Br. J. Obstet. Gynaecol, 89, (1982)

[3]

Swanson M., Sauerbrei E.E., Cooperberg P.L., Medical implications of ultrasonically detected polycystic ovaries, J. Clin. Ultrasound, 9, (1981)

[4]

Adams J., Franks S., Poison D.W., Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone, Lancet, 2, (1985)

[5]

Rebar R., Judd H.L., Yen S.S.C., Rakoff J., Vandenberg G., Naftolin F., Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome, J. Clin. Invest, 57, (1976)

[6]

Butler J.K., Clinical results with human gonadotrophins in anovulation, using two different alternative dosage schemes, Postgrad. Med. J, 48, (1972)

[7]

Donaldson A., Jeffcoate S.L., Sufi S.B., ssay of oestradiol in saliva, Immunoassays of Steroids in Saliva, (1984)

[8]

Data sheet for Pergonal

[9]

Fowler R.E., Chan S.T.H., Edwards R.G., Walters D.E., Steptoe P.C., Steroidogenesis in human follicles approaching ovulation as judged from assays of follicular fluid, J. Endocrinol, 72, (1978)

[10]

Fowler R.E., Edwards R.G., Walters D.E., Chan S.T.H., Startle P.C., Steroidogenesis in preovulatory follicles of patients given human menopausal and chorionic gonadotrophins as judged by the radioimmunoassay of steroids in follicular fluid, J. Endocrinol, 77, (1978)

← 1 →